DAUTOIM - Artigos
Permanent URI for this collection
Browse
Browsing DAUTOIM - Artigos by Subject "Antibodies, Monoclonal, Humanized / therapeutic use"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- Recent Developments in Biologic Therapies for the Treatment of Patients with Systemic Lupus ErythematosusPublication . Carreira, P; Isenberg, DSLE has a complex pathogenesis, and multiple therapeutic targets have been discovered in recent years. In spite of belimumab being approved by the US Food and Drug Administration and the widespread use of rituximab, there have been many failed attempts to treat SLE successfully using biologic agents. In this review, we consider newer biologic approaches that might offer the hope of improving the outcome of SLE patients. These include the fully humanized anti-CD20 mAbs, PEGylated anti-CD40L, IFNα inhibitors, rigerimod and immune complexes blockade.
- SAPHO: Has the Time Come for Tailored Therapy?Publication . Figueiredo, AS; Oliveira, AL; Caetano, A; Moraes-Fontes, MFSAPHO (synovitis, acne, pustulosis, hyperostosis and osteitis) syndrome is a heterogeneous condition combining osteoarticular and cutaneous manifestations. Conventional treatments are mostly ineffective. We hereby report two patients, the first with an aggressive form of disease and the second with an incomplete response to two different anti-TNF-α agents. Both were successfully treated with tocilizumab and ustekinumab, respectively, over a long period of time. A narrative review of a biological therapy in SAPHO syndrome yielded very little information on the specific use of these agents. We highlight the advantages of personalising therapy and describe emerging promising treatments for this disease.